Avalo Therapeutics
AVTX
5 hedge funds and large institutions have $1.58M invested in Avalo Therapeutics in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 4 closing their positions.
38% less funds holding
Funds holding: 8 → 5 (-3)
70% less capital invested
Capital invested by funds: $5.32M → $1.58M (-$3.74M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
RBF Capital
San Francisco,
California
|
+$36.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$2.22M |
| 2 |
Goldman Sachs
New York
|
-$194K |
| 3 |
BCCM
Blue Clay Capital Management
Minneapolis,
Minnesota
|
-$118K |
| 4 |
Millennium Management
New York
|
-$81.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$18.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $1.31M | – | – | – |
|
|
PWAM
2
Park West Asset Management
San Francisco,
California
| $200K | – | – | – |
|
|
3
Millennium Management
New York
| $29K | -$81.8K | -9 | -64% |
|
|
RC
4
RBF Capital
San Francisco,
California
| $24K | +$36.4K | +4 | New |
|
|
BCCM
5
Blue Clay Capital Management
Minneapolis,
Minnesota
| $11K | -$118K | -13 | -87% |
|
|
BFA
6
BlackRock Fund Advisors
San Francisco,
California
| $3K | – | – | – |
|
7
UBS Group
Zurich,
Switzerland
| $2K | -$9.09K | -1 | Closed |
|
|
MAM
8
MPM Asset Management
Boston,
Massachusetts
| – | -$2.22M | -207 | Closed |
|
|
9
Goldman Sachs
New York
| – | -$194K | -18 | Closed |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$18.2K | -2 | Closed |
|
|
BIM
11
BlackRock Investment Management
Wilmington,
Delaware
| – | -$3K | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$3K | – | – |
|
AVTX Hedge Fund Activity: Q2 2016 in Review
5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2016, worth a combined $1.58M — down 70% from $5.32M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AVTX and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was RBF Capital, opening a new position worth an estimated $36.4K. The largest seller was MPM Asset Management, exiting entirely with an estimated $2.22M sold.
- 5 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2016, down from 8 in Q1 2016.
- Funds reported $1.58M of Avalo Therapeutics stock for Q2 2016, down 70% quarter-over-quarter.
- 1 fund opened new Avalo Therapeutics positions in Q2 2016 and 4 closed out, a net change of -3 holders.
- The largest Avalo Therapeutics buyer in Q2 2016 was RBF Capital, an estimated $36.4K added.
- The largest Avalo Therapeutics seller in Q2 2016 was MPM Asset Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2016.